---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-081604"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-20T00:08:53.029064+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences closes $4M public offering of common stock and warrants

## Summary
- Gross proceeds ~$4M from sale of 3,640,000 shares (or pre-funded warrants) plus warrants for up to 14,560,000 shares.
- Warrants exercise price $1.10/share, exercisable after stockholder approval, expire 5 years from initial exercise date.
- Net proceeds to fund Phase 1b study, clinical drug supply manufacture, preclinical work, and general corporate purposes.
- Roth Capital Partners acted as sole placement agent; offering closed May 29, 2025.

## SEC filing metadata
- accession: 0000950170-25-081604
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017025081604/0000950170-25-081604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017025081604/revb-20250528.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-081604
- JSON: https://secwatch.observer/filing/0000950170-25-081604.json
- Plain text: https://secwatch.observer/filing/0000950170-25-081604.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.